author-photo

Brian I. Rini

Cleveland Clinic
Case Western Reserve University

731

Papers

37092

Citations

Citation Trend

Filter By

Papers (505) Sort By

Journal Conference Others

349 Tolerability of tivozanib vs. sorafenib in elderly and/or immunotherapy-pretreated patients with metastatic renal cell cancer (mRCC) in TIVO-3

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Clinically Useful Biomarkers in Metastatic Renal Cell Carcinoma

2021 Oncology Times UK
- Brian I. Rini
Show All
- Source
- Cite
- Save
Citations (0)
633 Incorporating checkpoint inhibitors into cancer care: a study of the impact of digital education on clinical competence and practice patterns

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Are immune checkpoint combination therapies for intermediate and poor risk renal cell carcinoma better than immune checkpoint inhibitors combined with kinase inhibitors

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (0)
RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting.

2021 Contemporary Clinical Trials
Show All
- Source
- Cite
- Save
Citations (1)
906 Immunogenomic evaluation of clear cell renal carcinoma uncovers HK3 as a myeloid specific metabolic enzyme

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
417 Phase 3 study of pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib as first-line treatment for advanced renal cell carcinoma

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PS7-01: Characteristics and outcomes of SARS-CoV-2 infection in patients with invasive breast cancer (BC) from the COVID-19 and cancer consortium (CCC19) cohort study

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Survie conditionnelle et suivi à 5 ans dans l’étude checkmate 214 : Nivolumab + Ipilimumab (N+I) versus Sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (ACCR)

2021 Progres En Urologie
Show All
- Source
- Cite
- Save
Citations (0)
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial.

2021 European Urology
Show All
- Source
- Cite
- Save
Citations (6)